ECTRIMS 2023 Symposium: The Latest Developments in MS Classification and Treatment: From AI to Clinical Decision Making - European Medical Journal

ECTRIMS 2023 Symposium: The Latest Developments in MS Classification and Treatment: From AI to Clinical Decision Making

Neurology

This information is for Healthcare Professionals only.

This promotional video is organised and funded by Bristol Myers Squibb.


Click here for Prescribing Information

The ECTRIMS 2023 BMS-promotional Symposium entitled, The Latest Developments in MS Classification and Treatment: From AI to Clinical Decision Making, presents a thought-provoking view on the latest developments in the field of Multiple Sclerosis from novel concepts in Progression Independent of Relapse Activity (PIRA), latest advances on thalamic brain atrophy and cognition and the introduction of Artificial Intelligence (AI) in clinical care.

Prof. Carmen Tur takes us beyond the traditional view of disease progression captured as Confirmed Disability Progression into concepts of Relapse-Associate Worsening (RAW) and PIRA. Although PIRA is relatively new as a concept, Prof Tur proposes that the next evolution captures brain atrophy, cognitive impairment and other measures of neurodegeneration.

Prof. Eleonara Cocco reviews the earliest signs of clinical progression which are regional brain atrophy and cognitive dysfunction. She reviews data demonstrating that thalamic atrophy correlates more strongly with loss of cognitive processing speed than whole brain atrophy and presents the 1-year data from the ENLIGHTEN trial which evaluates the efficacy of ozanimod of patients with very early relapsing remitting multiple sclerosis..

Dr. Lawrence Steinman provides an update on the development and application of Al in MS. He reviews applications of AI from early diagnosis and disease course prediction to image analysis, customized treatment plans and patient monitoring and feedback. Although challenges remain in the clinical application of AI, this transformative technology has the potential to make a major impact in our understanding of MS pathophysiology and to transform disease detection, diagnosis, prognosis and response to treatment.

An interesting question and answer period wraps up the symposium.

IMM-GB-2300537 | Date of Prep: Jan 2024

Adverse events should be reported. Reporting forms and information can be found via:
Great Britain & Northern Ireland – The Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Goggle Play or
Apple App store;
Ireland – HPRA Pharmacovigilance at www.hpra.ie
Adverse events should also be reported to Bristol-Myers Squibb via [email protected] or
08007311736 (Great Britain & Northern Ireland); 1 800 749 749 (Ireland).

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>